Global Granulomatosis With Polyangiitis Treatment Insights 2025, Forecast To 2034
26 Mar, 2025
How Has the Granulomatosis With Polyangiitis Treatment Market Evolved Historically and What is its Current Size?
The granulomatosis with polyangiitis treatment market has seen considerable growth due to a variety of factors.
• The market for treatments of granulomatosis with polyangiitis has been experiencing significant growth lately. The market size is projected to rise from $2.36 billion in 2024 to $2.56 billion in 2025, displaying a compound annual growth rate (CAGR) of 8.2%.
Factors contributing to the growth during the historical period included an increasing demand for these drugs, a surge in clinical trials, a heightened call for effective treatments, a growing focus on personalized medicine, and an increase in diagnosis of the disorder.
What is the Forecasted Market Size and CAGR for the Granulomatosis With Polyangiitis Treatment Market?
The granulomatosis with polyangiitis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of granulomatosis with polyangiitis treatment is predicted to experience substantial expansion in the coming years, reaching a value of $3.47 billion in 2029, representing a compound annual growth rate (CAGR) of 7.9%.
The market's growth can be credited to a variety of factors, including rising autoimmune disease prevalence, growing occurrences of granulomatosis and polyangiitis, and an increase in immunological disorder cases. Key trends projected for the future include progress in drug creation, healthcare developments, advancements in diagnostic methods, improvement in treatment choices, and the production of biologics and biosimilars.
What Key Factors and Trends Are Driving The Growth Granulomatosis With Polyangiitis Treatment Market?
The rise in autoimmune diseases is anticipated to drive the expansion of the granulomatosis with polyangiitis treatment market. Autoimmune diseases transpire when the body's immune system erroneously assaults its healthy cells and tissues, resulting in inflammation and harm in various organs. This uptick in autoimmune diseases can be attributed to environmental triggers (such as infections, chemicals, or pollutants) and changes in lifestyle. Treatments for granulomatosis with polyangiitis prove beneficial for autoimmune disorders by applying immunosuppressive therapies such as corticosteroids and cyclophosphamide; these treatments curb inflammation and avert organ damage, establishing their significance in early intervention and customized treatment for managing other autoimmune diseases with similar mechanics. To illustrate, a report by the UK-based Office for National Statistics in June 2023 revealed the global population of individuals with multiple sclerosis (an autoimmune disease) in 2023 had grown to 2.9 million from 2.8 million in 2022. Thus, the swelling prevalence of autoimmune diseases is fueling the granulomatosis with polyangiitis treatment market's growth.
What Are The Market Segments In The Granulomatosis With Polyangiitis Treatment Market?
The granulomatosis with polyangiitis treatment market covered in this report is segmented –
1) By Drug Type: Steroids, Immunosuppressant, Other Drug Types
2) By Treatment Type: Immunosuppressants, Corticosteroids
3) By Route Of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab
3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Which Emerging Market Trends Are Altering The Granulomatosis With Polyangiitis Treatment Industry?
Major industry players in the treatment market for granulomatosis with polyangiitis are concentrating their efforts on the creation of innovative products, such as oral corticosteroids. These are designed to enhance disease control, lessen steroid usage's long-term side effects, and bring more effective therapeutic options to patients. Oral corticosteroids, commonly used in treating allergies, autoimmune diseases, and inflammatory conditions, are drugs that diminish inflammation and control the immune system. For example, in October 2024, the UK-based AstraZeneca plc announced that the European Union, a unified consortium of European nations focusing on political and economic aspects, had approved Fasenra (bevacizumab). This was for its function as an adjunct treatment for adult patients suffering from eosinophilic granulomatosis with polyangiitis (EGPA) that is either relapsing or resistant. This endorsement came on the heels of the successful MANDARA Phase III trial that highlighted Fasenra's capacity to induce remission and reduce dependence on oral corticosteroids among EGPA patients.
Who Are the Key Players In The Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the granulomatosis with polyangiitis treatment market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Sanofi S.A.
• AstraZeneca plc
• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Vertex Pharmaceuticals Incorporated
• Genentech Inc.. Incyte Corporation
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• ChemoCentryx Inc.
• Medac Pharma Inc.
• InflaRx GmbH
What Are The Regional Insights Into The Granulomatosis With Polyangiitis Treatment Market?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.